Close Menu

BMS

A Supreme Court decision against drug developers in Sorrell v. IMS Health could potentially hamper how pharmacy benefit managers can use physician prescription data to drive adoption of pharmacogenomically guided products.

The study measured phosphoproteome-wide changes in hematopoietic BaF3 cells in response to perturbation of several Src family kinases, identifying four SFK negative feedback mechanisms that appear to be suppressed in cell lines resistant to the drug.

Under the deal, which follows on a previous collaboration between the companies entered in 2008, Kinaxo will apply its quantitative phosphoproteomics platform PhosphoScout to assist in drug development.

The data covers how 3,800 different inhibitors affect 172 kinases. The researchers grouped the proteins based both on sequence and pharmacological relationships and by their interactions with various compound chemotypes.

Under the extension, KineMed will grant BMS a non-exclusive license to its technology for the identification and characterization of Alzheimer's biomarkers in cerebrospinal fluid.

Under the extension, KineMed is granting Bristol-Myers Squibb a non-exclusive license to KineMed's technology for the identification and characterization of AD biomarkers in cerebrospinal fluid.

The company said that it will work with BMS to investigate the utility of its technology for diagnosis of Alzheimer's disease and for identifying individuals with early-stage cognitive impairment that are likely to progress to Alzheimer's disease.

The agreement calls for Kinaxo to provide quantitative analyses of PTMs on a proteome-wide scale with the expectation that "such comprehensive analysis will gain valuable insights into cellular functions of potential drug targets," the company said in a statement.

A plasma-based biomarker test for Alzheimer's could serve as a useful initial screen for the disease, as well as provide drugmakers with a way of selecting trial subjects that could be considerably less expensive than current methods like CSF analysis and PET scans.

The trial, called Biomarkers of Anti-TNF Treatment Efficacy in Rheumatoid Arthritis to Define Unresponse Populations, or BATTER-UP, will enroll around 1,000 patients being treated by one of several marketed anti-TNF RA drugs: Enbrel, Remicade, Humira, Simponi, or Cimzia.

Pages

Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.

The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.

Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.

In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.